search
Back to results

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise)

Primary Purpose

Migraine

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Placebo
Eptinezumab
Sponsored by
H. Lundbeck A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Migraine

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • The patient has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at screening visit with a history of migraine onset at least 12 months prior to the Screening Visit.
  • The patient has a migraine onset at ≤50 years of age.
  • The patient has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit.
  • The patient fulfils the following criteria for migraine in prospectively collected information in the eDiary during the screening period:
  • Migraine occurring on ≥8 days and headache occurring on ≥15 to ≤26 days.
  • The patient has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit.
  • The patient is aged ≥18 (≥20 for Taiwan) and ≤75 years at the Screening Visit.

Exclusion Criteria:

  • The patient has received any medication targeting the calcitonin gene-related peptide (CGRP) pathway as preventive treatment of migraine.
  • The patient has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • The patient has a diagnosis of acute or active temporomandibular disorder.
  • The patient has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration).
  • The patient has a lifetime history of psychosis, bipolar mania, or dementia.
  • Patients with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded.
  • The patient has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism).

Other inclusion and exclusion criteria may apply

Sites / Locations

  • The First Affiliated Hospital of Guangzhou Medical UniversityRecruiting
  • Renmin Hospital of Wuhan UniversityRecruiting
  • Beijing Chaoyang Hospital Capital Medical UniversityRecruiting
  • Xuanwu Hospital Capital Medical UniversityRecruiting
  • Chinese PLA General HospitalRecruiting
  • Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University)Recruiting
  • The First Hospital of Jilin UniversityRecruiting
  • The Second Hospital of Jilin UniversityRecruiting
  • The First Affiliated Hospital of Chongqing Medical UniversityRecruiting
  • The Affiliated Hospital of Guizhou Medical UniversityRecruiting
  • Jiangxi Pingxiang People's HospitalRecruiting
  • Union Hospital Tongji Medical College Huazhong University of Science and TechnologyRecruiting
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityRecruiting
  • People's Hospital of ZhengzhouRecruiting
  • The First Affiliated Hospital of Zhengzhou UniversityRecruiting
  • Pineo Medical EcosystemRecruiting
  • Aversi Clinic LTDRecruiting
  • S. Khechinashvili University Clinic, Ltd.Recruiting
  • Nakamura Memorial HospitalRecruiting
  • Iwate Medical University Uchimaru Medical CenterRecruiting
  • Sendai Headache and Cranial Nerves ClinicRecruiting
  • Makabe ClinicRecruiting
  • Saitama Neuropsychiatric InstituteRecruiting
  • Tokyo Dental College Ichikawa General HospitalRecruiting
  • Moriyama Neurological Center HospitalRecruiting
  • Shinagawa strings clinicRecruiting
  • Fukuuchi Pain ClinicRecruiting
  • Nagamitsu ClinicRecruiting
  • DOI Clinic Internal MedicineRecruiting
  • Atsuchi Neurosurgery HospitalRecruiting
  • Ikeda Neurosurgical ClinicRecruiting
  • Jinnouchi Neurosurgery ClinicRecruiting
  • Shin Matsudakai Atago HospitalRecruiting
  • Tatsuoka Neurology ClinicRecruiting
  • Dokkyo Medical University HospitalRecruiting
  • Mito Kyodo General HospitalRecruiting
  • Tominaga HospitalRecruiting
  • Tokyo headache clinicRecruiting
  • Japanese Red Cross Shizuoka HospitalRecruiting
  • Eiju General HospitalRecruiting
  • Toyota Memorial HospitalRecruiting
  • Inje University Ilsan Paik Hospital
  • Chungnam National University Hospital
  • Hallym University Dongtan Sacred Heart Hospital
  • Nowon Eulji Medical Center, Eulji University
  • Seoul National University Hospital
  • Kangbuk Samsung Hospital
  • Severance Hospital Yonsei University Health System
  • Asan Medical CenterRecruiting
  • Samsung Medical Center
  • ETG Lublin - PPDSRecruiting
  • ETG Zamosc - PPDSRecruiting
  • Instytut Zdrowia Dr Boczarska-JedynakRecruiting
  • MTZ Clinical Research Powered by PRATIA - PPDSRecruiting
  • ETG Singua - PPDSRecruiting
  • Centrum Medyczne Gdynia - PRATIA - PPDSRecruiting
  • Centrum Medyczne Silmedic Sp z o oRecruiting
  • Solumed SC-Dabrowskiego 77aRecruiting
  • Centrum Medyczne Katowice - PRATIA - PPDSRecruiting
  • Kiepury ClinicRecruiting
  • MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-DworakRecruiting
  • Hospital Universitario Vall d'Hebron - PPDSRecruiting
  • C.H. Regional Reina Sofia - PPDSRecruiting
  • Hospital Universitari Arnau de VilanovaRecruiting
  • Hospital Universitario La Paz - PPDSRecruiting
  • Hospital Universitario HM Sanchinarro - CIOCCRecruiting
  • Hospital Universitario Virgen MacarenaRecruiting
  • Hospital Universitario Virgen del Rocio - PPDSRecruiting
  • Hospital Clinico Universitario de Valencia
  • Hospital Universitari i Politecnic La Fe de ValenciaRecruiting
  • Hospital Clinico Universitario de ValladolidRecruiting
  • Hospital Clinico Universitario Lozano Blesa
  • Taipei Veterans General Hospital
  • Tri-Service General Hospital
  • Chang Gung Memorial Hospital, Linkou

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Eptinezumab 300 mg

Eptinezumab 100 mg

Placebo

Arm Description

300 mg eptinezumab by intravenous (IV) infusion.

100 mg eptinezumab by IV infusion.

Placebo by IV infusion.

Outcomes

Primary Outcome Measures

Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)

Secondary Outcome Measures

Response: ≥50% reduction from baseline in MMDs (Weeks 1-12)
Response: ≥75% reduction from baseline in MMDs (Weeks 1-4)
Response: ≥75% reduction from baseline in MMDs, (Weeks 1-12)
Migraine rate on the day after dosing
Response: ≥50% reduction from baseline in monthly headache days (MHDs) (Weeks 1-12)
Change from baseline in the number of MHDs (Weeks 1-12)
Response: ≥75% reduction from baseline in MHDs (Weeks 1-4)
Change from baseline in rate of migraines with severe pain intensity (Weeks 1-12)
Change from baseline in rate of headaches with severe pain intensity (Weeks 1-12)
Change from baseline in the number of MMDs with use of acute medication (Weeks 1-12)
Patient Global Impression of Change (PGIC) score at week 12
Most Bothersome Symptom (MBS) score at Week 12, as measured relative to Screening
Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score
Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)
Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score
Health Care Resources Utilization (HCRU)
Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.
Change from baseline to Week 12 in the Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)

Full Information

First Posted
June 4, 2021
Last Updated
October 12, 2023
Sponsor
H. Lundbeck A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04921384
Brief Title
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
Acronym
Sunrise
Official Title
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of Eptinezumab for the Preventive Treatment of Migraine
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 29, 2021 (Actual)
Primary Completion Date
October 22, 2024 (Anticipated)
Study Completion Date
March 11, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
H. Lundbeck A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study evaluates the efficacy of eptinezumab to prevent migraine in participants with chronic migraine.
Detailed Description
This is an interventional, multi-regional, multi-site, randomized, double-blind, placebo-controlled Phase III study, to confirm the efficacy and safety of eptinezumab in participants with chronic migraine who are eligible for preventive treatment. participants will be randomly allocated to one of three treatment groups: eptinezumab 300 mg, eptinezumab 100 mg, or placebo. The double-blind, placebo-controlled treatment period will be followed by an extension period where all participants will receive active treatment to further assess the safety and tolerability of eptinezumab. The total study duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Extension Period (12 weeks), and a Safety Follow-up Period (8 weeks).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
945 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Eptinezumab 300 mg
Arm Type
Experimental
Arm Description
300 mg eptinezumab by intravenous (IV) infusion.
Arm Title
Eptinezumab 100 mg
Arm Type
Experimental
Arm Description
100 mg eptinezumab by IV infusion.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo by IV infusion.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
0.9% normal saline, intravenously
Intervention Type
Drug
Intervention Name(s)
Eptinezumab
Other Intervention Name(s)
Lu AG09221
Intervention Description
Solution for infusion, intravenously
Primary Outcome Measure Information:
Title
Change from baseline in the number of monthly migraine days (MMDs) (Weeks 1-12)
Time Frame
Weeks 1-12
Secondary Outcome Measure Information:
Title
Response: ≥50% reduction from baseline in MMDs (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Response: ≥75% reduction from baseline in MMDs (Weeks 1-4)
Time Frame
Weeks 1-4
Title
Response: ≥75% reduction from baseline in MMDs, (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Migraine rate on the day after dosing
Time Frame
Day 1
Title
Response: ≥50% reduction from baseline in monthly headache days (MHDs) (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Change from baseline in the number of MHDs (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Response: ≥75% reduction from baseline in MHDs (Weeks 1-4)
Time Frame
Weeks 1-4
Title
Change from baseline in rate of migraines with severe pain intensity (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Change from baseline in rate of headaches with severe pain intensity (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Change from baseline in the number of MMDs with use of acute medication (Weeks 1-12)
Time Frame
Weeks 1-12
Title
Patient Global Impression of Change (PGIC) score at week 12
Time Frame
Week 12
Title
Most Bothersome Symptom (MBS) score at Week 12, as measured relative to Screening
Time Frame
Screening to Week 12
Title
Change from baseline to Week 12 in the Headache Impact Test (HIT-6) score
Time Frame
Baseline to Week 12
Title
Change from baseline to Week 12 in the Migraine-Specific Quality of Life (MSQ v2.1) sub-scores (Role Function-Restrictive, Role Function-Preventive, Emotional Function)
Time Frame
Baseline to Week 12
Title
Change from baseline to Week 12 in the Health-Related Quality of Life (EQ-5D-5L) Visual Analogue Scale (VAS) score
Time Frame
Baseline to Week 12
Title
Health Care Resources Utilization (HCRU)
Description
Migraine-specific healthcare resource utilization information will be collected in terms of outpatient health care professional visits, emergency room visits, hospital admissions, as well as duration of hospital stays.
Time Frame
Baseline to Week 12
Title
Change from baseline to Week 12 in the Work Productivity and Activity Impairment Questionnaire: Migraine (WPAI:M) sub-scores (Absenteeism, Presenteeism, Work productivity loss, Activity impairment)
Time Frame
Baseline to Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The participant has a diagnosis of CM as defined by IHS ICHD-3 guidelines confirmed at screening visit with a history of migraine onset at least 12 months prior to the Screening Visit. The participant has a migraine onset at ≤50 years of age. The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit. The participant fulfils the following criteria for migraine in prospectively collected information in the eDiary during the screening period: Migraine occurring on ≥8 days and headache occurring on ≥15 to ≤26 days. The participant has demonstrated compliance with the Headache eDiary by entry of data for at least 24 of the 28 days following the Screening Visit. The participant is aged ≥18 (≥20 for Taiwan) and ≤75 years at the Screening Visit. Exclusion Criteria: The participant has received any medication targeting the calcitonin gene-related peptide (CGRP) pathway as preventive treatment of migraine. The participant has confounding and clinically significant pain syndromes, (for example, fibromyalgia, chronic low back pain, complex regional pain syndrome). The participant has a diagnosis of acute or active temporomandibular disorder. The participant has a history or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes such as hemiplegic migraine (sporadic and familial), ophthalmoplegic migraine, migraine with brainstem aura and migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration). The participant has a lifetime history of psychosis, bipolar mania, or dementia. Participants with other psychiatric conditions whose symptoms are not controlled or who have not been adequately treated for a minimum of 6 months prior to screening are also excluded. The participant has a history of clinically significant cardiovascular disease, including uncontrolled hypertension, vascular ischaemia or thromboembolic events (for example, cerebrovascular accident, deep vein thrombosis, or pulmonary embolism). Other inclusion and exclusion criteria may apply
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Email contact via H. Lundbeck A/S
Phone
+45 36301311
Email
LundbeckClinicalTrials@Lundbeck.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Email contact via H. Lundbeck A/S
Organizational Affiliation
LundbeckClinicalTrials@Lundbeck.com
Official's Role
Study Director
Facility Information:
Facility Name
The First Affiliated Hospital of Guangzhou Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China
Individual Site Status
Recruiting
Facility Name
Renmin Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430060
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Chaoyang Hospital Capital Medical University
City
Beijing
ZIP/Postal Code
100020
Country
China
Individual Site Status
Recruiting
Facility Name
Xuanwu Hospital Capital Medical University
City
Beijing
ZIP/Postal Code
100053
Country
China
Individual Site Status
Recruiting
Facility Name
Chinese PLA General Hospital
City
Beijing
ZIP/Postal Code
100853
Country
China
Individual Site Status
Recruiting
Facility Name
Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University)
City
Beijing
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Name
The First Hospital of Jilin University
City
Changchun
ZIP/Postal Code
130021
Country
China
Individual Site Status
Recruiting
Facility Name
The Second Hospital of Jilin University
City
Changchun
ZIP/Postal Code
130022
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Chongqing Medical University
City
Chongqing
ZIP/Postal Code
400016
Country
China
Individual Site Status
Recruiting
Facility Name
The Affiliated Hospital of Guizhou Medical University
City
Guiyang
ZIP/Postal Code
550000
Country
China
Individual Site Status
Recruiting
Facility Name
Jiangxi Pingxiang People's Hospital
City
Pingxiang
ZIP/Postal Code
337055
Country
China
Individual Site Status
Recruiting
Facility Name
Union Hospital Tongji Medical College Huazhong University of Science and Technology
City
Wuhan
ZIP/Postal Code
430022
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
ZIP/Postal Code
710061
Country
China
Individual Site Status
Recruiting
Facility Name
People's Hospital of Zhengzhou
City
Zhengzhou
ZIP/Postal Code
450003
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
ZIP/Postal Code
450052
Country
China
Individual Site Status
Recruiting
Facility Name
Pineo Medical Ecosystem
City
Tbilisi
ZIP/Postal Code
0114
Country
Georgia
Individual Site Status
Recruiting
Facility Name
Aversi Clinic LTD
City
Tbilisi
ZIP/Postal Code
0160
Country
Georgia
Individual Site Status
Recruiting
Facility Name
S. Khechinashvili University Clinic, Ltd.
City
Tbilisi
ZIP/Postal Code
179
Country
Georgia
Individual Site Status
Recruiting
Facility Name
Nakamura Memorial Hospital
City
Sapporo-Shi Chuo-Ku
State/Province
Hokkaidô
ZIP/Postal Code
060-0061
Country
Japan
Individual Site Status
Recruiting
Facility Name
Iwate Medical University Uchimaru Medical Center
City
Morioka
State/Province
Iwate
ZIP/Postal Code
020-8505
Country
Japan
Individual Site Status
Recruiting
Facility Name
Sendai Headache and Cranial Nerves Clinic
City
Sendai-Shi Taihaku-Ku
State/Province
Miyagi
ZIP/Postal Code
982-0014
Country
Japan
Individual Site Status
Recruiting
Facility Name
Makabe Clinic
City
Okayama-Shi Kita-Ku
State/Province
Okayama
ZIP/Postal Code
700-0964
Country
Japan
Individual Site Status
Recruiting
Facility Name
Saitama Neuropsychiatric Institute
City
Saitama-shi
State/Province
Saitama
ZIP/Postal Code
338-8577
Country
Japan
Individual Site Status
Recruiting
Facility Name
Tokyo Dental College Ichikawa General Hospital
City
Ichikawa-Shi
State/Province
Tiba
ZIP/Postal Code
272-0824
Country
Japan
Individual Site Status
Recruiting
Facility Name
Moriyama Neurological Center Hospital
City
Edogawa-ku
State/Province
Tokyo
ZIP/Postal Code
134-0085
Country
Japan
Individual Site Status
Recruiting
Facility Name
Shinagawa strings clinic
City
Minato-Ku
State/Province
Tokyo
ZIP/Postal Code
108-0075
Country
Japan
Individual Site Status
Recruiting
Facility Name
Fukuuchi Pain Clinic
City
Shinjuku
State/Province
Tokyo
ZIP/Postal Code
160-0017
Country
Japan
Individual Site Status
Recruiting
Facility Name
Nagamitsu Clinic
City
Hofu
State/Province
Yamaguti
ZIP/Postal Code
7470802
Country
Japan
Individual Site Status
Recruiting
Facility Name
DOI Clinic Internal Medicine
City
Hirosima Naka-ku
ZIP/Postal Code
730-0031
Country
Japan
Individual Site Status
Recruiting
Facility Name
Atsuchi Neurosurgery Hospital
City
Kagoshima-shi
ZIP/Postal Code
892-0842
Country
Japan
Individual Site Status
Recruiting
Facility Name
Ikeda Neurosurgical Clinic
City
Kasuga City
ZIP/Postal Code
816-0824
Country
Japan
Individual Site Status
Recruiting
Facility Name
Jinnouchi Neurosurgery Clinic
City
Kasuga-shi
ZIP/Postal Code
816-0802
Country
Japan
Individual Site Status
Recruiting
Facility Name
Shin Matsudakai Atago Hospital
City
Kochi-shi
ZIP/Postal Code
780-0051
Country
Japan
Individual Site Status
Recruiting
Facility Name
Tatsuoka Neurology Clinic
City
Kyoto Shimojo-ku
ZIP/Postal Code
680-8811
Country
Japan
Individual Site Status
Recruiting
Facility Name
Dokkyo Medical University Hospital
City
Mibu-Machi
ZIP/Postal Code
321-0293
Country
Japan
Individual Site Status
Recruiting
Facility Name
Mito Kyodo General Hospital
City
Mito-shi
ZIP/Postal Code
310-0015
Country
Japan
Individual Site Status
Recruiting
Facility Name
Tominaga Hospital
City
Naniwa-ku
ZIP/Postal Code
5560017
Country
Japan
Individual Site Status
Recruiting
Facility Name
Tokyo headache clinic
City
Shibuya-ku
ZIP/Postal Code
151-0051
Country
Japan
Individual Site Status
Recruiting
Facility Name
Japanese Red Cross Shizuoka Hospital
City
Shizuoka-shi
ZIP/Postal Code
420-0853
Country
Japan
Individual Site Status
Recruiting
Facility Name
Eiju General Hospital
City
Taito City
ZIP/Postal Code
110-8645
Country
Japan
Individual Site Status
Recruiting
Facility Name
Toyota Memorial Hospital
City
Toyota-shi
ZIP/Postal Code
471-8513
Country
Japan
Individual Site Status
Recruiting
Facility Name
Inje University Ilsan Paik Hospital
City
Goyang-si
State/Province
Gyeonggido
ZIP/Postal Code
10380
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Chungnam National University Hospital
City
Daejeon
ZIP/Postal Code
35015
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Hallym University Dongtan Sacred Heart Hospital
City
Gyeonggi-do
ZIP/Postal Code
18450
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Nowon Eulji Medical Center, Eulji University
City
Seoul
ZIP/Postal Code
01830
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Kangbuk Samsung Hospital
City
Seoul
ZIP/Postal Code
03181
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Severance Hospital Yonsei University Health System
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Completed
Facility Name
ETG Lublin - PPDS
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-412
Country
Poland
Individual Site Status
Recruiting
Facility Name
ETG Zamosc - PPDS
City
Zamosc
State/Province
Lubelskie
ZIP/Postal Code
22-400
Country
Poland
Individual Site Status
Recruiting
Facility Name
Instytut Zdrowia Dr Boczarska-Jedynak
City
Oswiecim
State/Province
Malopolskie
ZIP/Postal Code
32-600
Country
Poland
Individual Site Status
Recruiting
Facility Name
MTZ Clinical Research Powered by PRATIA - PPDS
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-172
Country
Poland
Individual Site Status
Recruiting
Facility Name
ETG Singua - PPDS
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-777
Country
Poland
Individual Site Status
Recruiting
Facility Name
Centrum Medyczne Gdynia - PRATIA - PPDS
City
Gdynia
State/Province
Pomorskie
ZIP/Postal Code
81-338
Country
Poland
Individual Site Status
Recruiting
Facility Name
Centrum Medyczne Silmedic Sp z o o
City
Katowice
State/Province
Slaskie
ZIP/Postal Code
40-282
Country
Poland
Individual Site Status
Recruiting
Facility Name
Solumed SC-Dabrowskiego 77a
City
Poznan
State/Province
Wielkopolskie
ZIP/Postal Code
60-101
Country
Poland
Individual Site Status
Recruiting
Facility Name
Centrum Medyczne Katowice - PRATIA - PPDS
City
Katowice
ZIP/Postal Code
40-081
Country
Poland
Individual Site Status
Recruiting
Facility Name
Kiepury Clinic
City
Sosnowiec
ZIP/Postal Code
41-209
Country
Poland
Individual Site Status
Recruiting
Facility Name
MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak
City
Wroclaw
ZIP/Postal Code
52-210
Country
Poland
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Vall d'Hebron - PPDS
City
Barcelona
ZIP/Postal Code
8035
Country
Spain
Individual Site Status
Recruiting
Facility Name
C.H. Regional Reina Sofia - PPDS
City
Cordoba
ZIP/Postal Code
14008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Arnau de Vilanova
City
Lleida
ZIP/Postal Code
25198
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario La Paz - PPDS
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario HM Sanchinarro - CIOCC
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
ZIP/Postal Code
41009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen del Rocio - PPDS
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitari i Politecnic La Fe de Valencia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valladolid
City
Valladolid
ZIP/Postal Code
47005
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario Lozano Blesa
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Completed
Facility Name
Taipei Veterans General Hospital
City
Taipei City
ZIP/Postal Code
11217
Country
Taiwan
Individual Site Status
Completed
Facility Name
Tri-Service General Hospital
City
Taipei
ZIP/Postal Code
11490
Country
Taiwan
Individual Site Status
Completed
Facility Name
Chang Gung Memorial Hospital, Linkou
City
Taoyuan City
ZIP/Postal Code
33305
Country
Taiwan
Individual Site Status
Completed

12. IPD Sharing Statement

Learn more about this trial

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

We'll reach out to this number within 24 hrs